Scopus BioPharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCPS research report →
Price Chart
About the company
Scopus BioPharma Inc. is a biopharmaceutical company in the clinical development phase, dedicated to pioneering innovative treatments for serious diseases. Its core development programs are concentrated on immuno-oncology gene therapies designed to combat various forms of cancer.
- CEO
- Alan D. Horsager
- IPO
- 2020
- Employees
- 13
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on SCPS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.83K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 911.69%
- ROIC
- 164.39%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,714,877
- Net Income
- $-11,609,827+58.1%
- EPS
- $-0.55+65.8%
- OCF Growth
- +28.9%
- FCF Growth
- +28.9%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.01
- RSI (14)
- 48
- Avg Volume
- 3.60K
No earnings-call transcripts are available for SCPS yet.
- Free Float
- 81.3%
- Shares Outstanding
- 42.08M
- Float Shares
- 34.22M
of shares held by institutions
12 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 23, 21 | Greenspan Ira Scott | other | 3,000,000 |
| Nov 23, 21 | Lamstein Joshua R | other | 3,000,000 |
| Jun 1, 21 | Hopper Paul | other | 6,333 |
| Dec 15, 20 | Hopper Paul | other | 0 |
| Oct 1, 21 | Hopper Paul | other | 0 |
| Oct 1, 21 | Hopper Paul | other | 0 |
| Dec 15, 20 | Hopper Paul | other | 0 |
| Aug 27, 21 | Greenspan Ira Scott | buy | 110 |
| Aug 27, 21 | Greenspan Ira Scott | buy | 790 |
| Aug 27, 21 | Lamstein Joshua R | buy | 200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SCPS coverage
Recent articles, reports, and earnings notes.
No research on SCPS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCPS report →Contrasting Scopus BioPharma (NASDAQ:SCPS) & MorphoSys (NASDAQ:MOR)
defenseworld.net · Dec 10
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
globenewswire.com · Nov 7
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
globenewswire.com · Nov 2
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
globenewswire.com · Mar 22
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
globenewswire.com · Oct 8
Scopus BioPharma to Present at the LD Micro Main Event
globenewswire.com · Oct 5
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
globenewswire.com · Oct 1
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
globenewswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.